CN112239507A - ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用 - Google Patents

ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用 Download PDF

Info

Publication number
CN112239507A
CN112239507A CN201910645466.XA CN201910645466A CN112239507A CN 112239507 A CN112239507 A CN 112239507A CN 201910645466 A CN201910645466 A CN 201910645466A CN 112239507 A CN112239507 A CN 112239507A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
ser
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910645466.XA
Other languages
English (en)
Chinese (zh)
Inventor
张�成
药晨江
章华
汪笑峰
景书谦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hongyun Huaning Hangzhou Biomedical Co ltd
Original Assignee
Hongyun Huaning Hangzhou Biomedical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hongyun Huaning Hangzhou Biomedical Co ltd filed Critical Hongyun Huaning Hangzhou Biomedical Co ltd
Priority to CN201910645466.XA priority Critical patent/CN112239507A/zh
Priority to CA3147687A priority patent/CA3147687A1/en
Priority to PCT/CN2020/101857 priority patent/WO2021008519A1/zh
Priority to CN202080051495.4A priority patent/CN114127126B/zh
Priority to US17/627,089 priority patent/US12473369B2/en
Priority to EP20840563.9A priority patent/EP4008731A4/en
Priority to JP2022502538A priority patent/JP7809632B2/ja
Priority to KR1020227004194A priority patent/KR20220035155A/ko
Priority to BR112022000883A priority patent/BR112022000883A2/pt
Priority to MX2022000452A priority patent/MX2022000452A/es
Priority to AU2020313155A priority patent/AU2020313155A1/en
Priority to TW109124139A priority patent/TWI897870B/zh
Publication of CN112239507A publication Critical patent/CN112239507A/zh
Priority to JP2025092565A priority patent/JP2025143267A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
CN201910645466.XA 2019-07-17 2019-07-17 ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用 Pending CN112239507A (zh)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CN201910645466.XA CN112239507A (zh) 2019-07-17 2019-07-17 ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用
KR1020227004194A KR20220035155A (ko) 2019-07-17 2020-07-14 ETA 항체 및 TGF-β TRAP의 융합 단백질 및 이의 약제학적 조성물 및 응용
BR112022000883A BR112022000883A2 (pt) 2019-07-17 2020-07-14 Proteína de fusão de um anticorpo eta e de um supressor de tgf-ss, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica e uso de uma composição farmacêutica
CN202080051495.4A CN114127126B (zh) 2019-07-17 2020-07-14 ETA抗体与TGF-βTrap的融合蛋白质，以及其药物组合物和应用
US17/627,089 US12473369B2 (en) 2019-07-17 2020-07-14 Fusion protein of anti-eta antibody and tgf-beta trap and pharmaceutical composition and application thereof in method of treatment
EP20840563.9A EP4008731A4 (en) 2019-07-17 2020-07-14 ETA ANTIBODY-TGF-BETA TRAP FUSION PROTEIN AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
JP2022502538A JP7809632B2 (ja) 2019-07-17 2020-07-14 ＥＴＡ抗体及びＴＧＦ－β Ｔｒａｐの融合タンパク質及びその医薬組成物並びに用途
CA3147687A CA3147687A1 (en) 2019-07-17 2020-07-14 Fusion protein of eta antibody and tgf-ss trap and pharmaceutical composition and application thereof
PCT/CN2020/101857 WO2021008519A1 (zh) 2019-07-17 2020-07-14 ETA抗体与TGF-βTrap的融合蛋白质，以及其药物组合物和应用
MX2022000452A MX2022000452A (es) 2019-07-17 2020-07-14 Proteína de fusión del anticuerpo eta y trampa de tgf-¿ y composición farmacéutica y aplicación de la misma.
AU2020313155A AU2020313155A1 (en) 2019-07-17 2020-07-14 Fusion protein of ETA antibody and TGF-β trap and pharmaceutical composition and application thereof
TW109124139A TWI897870B (zh) 2019-07-17 2020-07-16 ETA抗體與TGF-β Trap的融合蛋白質，以及其藥物組合物和應用
JP2025092565A JP2025143267A (ja) 2019-07-17 2025-06-03 ＥＴＡ抗体及びＴＧＦ－β Ｔｒａｐの融合タンパク質及びその医薬組成物並びに用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910645466.XA CN112239507A (zh) 2019-07-17 2019-07-17 ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用

Publications (1)

Publication Number Publication Date
CN112239507A true CN112239507A (zh) 2021-01-19

Family

ID=74167347

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910645466.XA Pending CN112239507A (zh) 2019-07-17 2019-07-17 ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用
CN202080051495.4A Active CN114127126B (zh) 2019-07-17 2020-07-14 ETA抗体与TGF-βTrap的融合蛋白质，以及其药物组合物和应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080051495.4A Active CN114127126B (zh) 2019-07-17 2020-07-14 ETA抗体与TGF-βTrap的融合蛋白质，以及其药物组合物和应用

Country Status (11)

Country Link
US (1) US12473369B2 (https=)
EP (1) EP4008731A4 (https=)
JP (2) JP7809632B2 (https=)
KR (1) KR20220035155A (https=)
CN (2) CN112239507A (https=)
AU (1) AU2020313155A1 (https=)
BR (1) BR112022000883A2 (https=)
CA (1) CA3147687A1 (https=)
MX (1) MX2022000452A (https=)
TW (1) TWI897870B (https=)
WO (1) WO2021008519A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022184015A1 (zh) * 2021-03-01 2022-09-09 长春金赛药业有限责任公司 抗体融合蛋白及其应用
WO2022206857A1 (zh) * 2021-03-31 2022-10-06 鸿运华宁（杭州）生物医药有限公司 一种能与人内皮素受体特异性结合的抗体及其在糖尿病肾病和慢性肾病治疗中的应用
CN115181185A (zh) * 2021-04-02 2022-10-14 苏州普乐康医药科技有限公司 一种结合ctgf的融合蛋白及其应用
WO2022262733A1 (zh) * 2021-06-17 2022-12-22 鸿运华宁（杭州）生物医药有限公司 一种能与人eta和人cd3结合的双特异性抗体及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250155046A (ko) * 2023-03-09 2025-10-29 테릭스 파마슈티컬스 (이노베이션스) 피티와이 엘티디 다작용성 항체

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104371019A (zh) * 2013-08-13 2015-02-25 杭州鸿运华宁生物医药工程有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
CN107987162A (zh) * 2016-10-27 2018-05-04 鸿运华宁（杭州）生物医药有限公司 Etar抗体，其药物组合物及其应用
CN108348589A (zh) * 2015-09-18 2018-07-31 安驰肿瘤公司 治疗性cd47抗体
CN108368176A (zh) * 2015-10-01 2018-08-03 波滕扎治疗公司 抗tigit抗原结合蛋白及其使用方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
ATE240394T1 (de) 1992-10-23 2003-05-15 Immunex Corp Methoden zur herstellung löslicher, oligomerer proteine
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
MX2008011227A (es) 2006-03-03 2009-02-10 Torrent Pharmaceuticals Ltd Receptores antagonistas de accion nueva y doble en los receptores at1 y eta.
UA109888C2 (uk) * 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
HK1197159A1 (en) * 2011-05-25 2015-01-09 Intermune, Inc. Pirfenidone and anti-fibrotic therapy in selected patients
WO2015077540A2 (en) 2013-11-21 2015-05-28 The Brigham And Women's Hospital, Inc. Compositions and methods for treating pulmonary hypertension
US9676863B2 (en) 2014-02-10 2017-06-13 Merck Patent Gmbh Targeted TGFβ inhibitors
US9750761B2 (en) * 2014-05-21 2017-09-05 University Of Rochester LDH inhibitors as treatment for fibrosis and fibrotic-related disorders
CN111018987B (zh) * 2014-12-05 2023-11-21 鸿运华宁（杭州）生物医药有限公司 一种能与人内皮素受体特异性结合的抗体及其应用
US20200231652A1 (en) 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
TWI826351B (zh) 2016-05-31 2023-12-21 大陸商鴻運華寧（杭州）生物醫藥有限公司 Ｒ抗體,其藥物組合物及其應用
JP7075135B2 (ja) * 2016-08-16 2022-05-25 ユニヴァーシティ オヴ メリーランド、バルティモア 増殖因子を標的とする二機能性分子を使用したがんの治療方法
LT3628049T (lt) 2017-05-04 2023-08-25 Acceleron Pharma Inc. Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104371019A (zh) * 2013-08-13 2015-02-25 杭州鸿运华宁生物医药工程有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
CN108348589A (zh) * 2015-09-18 2018-07-31 安驰肿瘤公司 治疗性cd47抗体
CN108368176A (zh) * 2015-10-01 2018-08-03 波滕扎治疗公司 抗tigit抗原结合蛋白及其使用方法
CN107987162A (zh) * 2016-10-27 2018-05-04 鸿运华宁（杭州）生物医药有限公司 Etar抗体，其药物组合物及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAVID ALVAREZ 等: "A novel role of endothelin-1 in linking Toll-like receptor 7-mediated inflammation to fibrosis in congenital heart block", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 286, no. 35, pages 30444 - 30454 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022184015A1 (zh) * 2021-03-01 2022-09-09 长春金赛药业有限责任公司 抗体融合蛋白及其应用
WO2022206857A1 (zh) * 2021-03-31 2022-10-06 鸿运华宁（杭州）生物医药有限公司 一种能与人内皮素受体特异性结合的抗体及其在糖尿病肾病和慢性肾病治疗中的应用
CN115181185A (zh) * 2021-04-02 2022-10-14 苏州普乐康医药科技有限公司 一种结合ctgf的融合蛋白及其应用
CN115181185B (zh) * 2021-04-02 2025-08-08 苏州普乐康医药科技有限公司 一种结合ctgf的融合蛋白及其应用
WO2022262733A1 (zh) * 2021-06-17 2022-12-22 鸿运华宁（杭州）生物医药有限公司 一种能与人eta和人cd3结合的双特异性抗体及其应用

Also Published As

Publication number Publication date
JP7809632B2 (ja) 2026-02-02
AU2020313155A1 (en) 2022-02-17
CA3147687A1 (en) 2021-01-21
EP4008731A4 (en) 2023-07-19
EP4008731A1 (en) 2022-06-08
US20220265771A1 (en) 2022-08-25
JP2022540918A (ja) 2022-09-20
TW202108630A (zh) 2021-03-01
CN114127126A (zh) 2022-03-01
KR20220035155A (ko) 2022-03-21
TWI897870B (zh) 2025-09-21
CN114127126B (zh) 2024-08-09
US12473369B2 (en) 2025-11-18
BR112022000883A2 (pt) 2022-03-08
MX2022000452A (es) 2022-04-25
WO2021008519A1 (zh) 2021-01-21
JP2025143267A (ja) 2025-10-01

Similar Documents

Publication Publication Date Title
CN111018987B (zh) 一种能与人内皮素受体特异性结合的抗体及其应用
CN112239507A (zh) ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用
AU2020350715A1 (en) GIPR antibody and fusion protein between same and GLP-1, and pharmaceutical composition and application thereof
KR102669444B1 (ko) Etar 항체 및 이의 약학 조성물 및 용도
KR20200133365A (ko) Gipr 항체 및 이와 glp-1의 융합 단백질, 및 그의 약학 조성물 및 적용
CN112062857B (zh) Eta抗体与bnp的融合蛋白质，及其药物组合物和应用
RU2832190C2 (ru) СЛИТЫЙ БЕЛОК НА ОСНОВЕ АНТИТЕЛА К ЕТА И TGF-β TRAP, СОДЕРЖАЩАЯ ЕГО ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ИХ ПРИМЕНЕНИЕ
HK40036828A (en) FUSION PROTEIN OF ETA ANTIBODY AND TGF-β TRAP AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF
HK40036359A (en) Fusion protein of eta antibody and bnp, and its pharmaceutical composition and application
TW202304982A (zh) 一種能與人內皮素受體特異性結合的抗體及其在糖尿病腎病及慢性腎病治療中的應用
HK40081863A (en) Antibody capable of specifically binding to human endothelin receptor, and use thereof in treatment of diabetic nephropathy and chronic nephropathy
RU2800370C2 (ru) Антитело к gipr и его слитый с glp-1 белок, а также фармацевтическая композиция на его основе и его применение
KR20210019535A (ko) Apj 항체 및 이와 엘라벨라의 융합 단백질, 및 그의 약학 조성물 및 적용
HK40036359B (zh) Eta抗体与bnp的融合蛋白质，及其药物组合物和应用
HK40024246A (en) An antibody that specifically binds to human endothelin receptor and use thereof
HK40024246B (zh) 一种能与人内皮素受体特异性结合的抗体及其应用
HK40040729A (en) Gipr antibody and fusion protein of gipr antibody and glp-1, and pharmaceutical composition and application thereof
HK1254918A1 (zh) Etar抗体，其药物组合物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40036828

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210119